{"nctId":"NCT00599196","briefTitle":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease","startDateStruct":{"date":"2002-08"},"conditions":["Early Stage Parkinson's Disease"],"count":381,"armGroups":[{"label":"Rotigotine","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]}],"interventions":[{"name":"Rotigotine","otherNames":["NeuproÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who have completed six months of maintenance treatment in the SP513 double-blind trial\n\nExclusion Criteria:\n\n* Subjects who had an ongoing serious adverse event from SP513 double-blind trial that was assessed as related to study medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"369","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Withdrew From the Trial Due to an Adverse Event","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Epworth Sleepiness Scale Score During the Open-label Extension","description":"The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"4.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":131,"n":380},"commonTop":["Somnolence","Nausea","Oedema peripheral","Back pain","Dizziness"]}}}